VJHemOnc is committed to improving our service to you

ASCO 2019 | ECOG-E3A06: lenalidomide vs. observation alone in SMM

VJHemOnc is committed to improving our service to you

Sagar Lonial

Sagar Lonial, MD, FACP, from the Winship Cancer Institute, Druid Hills, GA, gives us an update on ECOG-E3A06 (NCT01169337), a Phase III randomized trial investigating lenalidomide versus observation alone in asymptomatic high-risk smoldering multiple myeloma (SMM). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter